BioCentury | Nov 20, 2014
Cover Story

Tapping TOPK

...Sciences Inc. and Galen Ltd. and Myocet liposomal doxorubicin from Teva Pharmaceutical Industries Ltd. and Sopherion Therapeutics LLC...
...U.K. Nerviano Medical Sciences s.r.l. , Nerviano, Italy OncoTherapy Science Inc. (Tokyo:4564), Kawasaki City, Japan Sopherion Therapeutics LLC...
BioCentury | Jul 5, 2010
Finance

2H10 milestones

...Osaka:4506) Calsed amrubicin Second-line small cell lung cancer (SCLC) Ph III data YE10 Cephalon Inc. (NASDAQ:CEPH)/Sopherion Therapeutics LLC...
BioCentury | Apr 8, 2010
Distillery Techniques

Technology: Drug delivery

...treat cancer. Johnson & Johnson markets Doxil doxorubicin to treat several cancers. Cephalon Inc. and Sopherion Therapeutics LLC...
BioCentury | Jan 11, 2010
Clinical News

Myocet doxorubicin regulatory update

...FDA granted Fast Track designation for Sopherion's Myocet nonpegylated liposomal doxorubicin for first-line treatment of HER2-positive...
...is in a Phase III trial for the indication, with results expected by year end. Sopherion...
...which was acquired by Cephalon (see BioCentury, Dec. 12, 2005). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Sopherion Therapeutics LLC...
BioCentury | Mar 23, 2009
Clinical News

Myocet doxorubicin: Completed Phase III enrollment

...an open-label, international Phase III trial evaluating Herceptin trastuzumab and paclitaxel with or without Myocet. Sopherion...
...Basel, Switzerland) and Genentech Inc. (NYSE:DNA, South San Francisco, Calif.). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Sopherion Therapeutics LLC...
BioCentury | Mar 2, 2009
Company News

Sopherion management update

Sopherion Therapeutics LLC , Princeton, N.J. Business: Cancer Hired: Marcel Rozencweig as senior EVP of clinical affairs, while remaining an adjunct associate professor of medicine at New York University WIR Staff cancer Other...
BioCentury | Feb 20, 2009
Financial News

Sopherion raises $55 million

...Venture Partners/Sprout Group; ProQuest Investments; Canaan Partners; Commerce Bank; and NewSpring Capital in the round. Sopherion's...
...Myocet liposomal doxorubicin, which is in Phase III testing to treat first-line metastatic breast cancer. Sopherion...
BioCentury | Feb 9, 2009
Clinical News

Myocet doxorubicin: Phase I/II data

...of metastatic breast cancer in combination with cyclophosphamide. Cephalon has European rights to Myocet, and Sopherion...
...by Roche and Genentech Inc. (NYSE:DNA, South San Francisco, Calif.). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Sopherion Therapeutics LLC...
BioCentury | Jan 15, 2009
Distillery Therapeutics

Indication: Cancer

...for angina and hypertension. Myocet doxorubicin, a liposomal formulation of doxorubicin from Cephalon Inc. and Sopherion...
BioCentury | Sep 25, 2008
Distillery Techniques

This Week in Techniques

...additional preclinical cancer models. Myocet doxorubicin, a liposomal formulation of doxorubicin from Cephalon Inc. and Sopherion...
Items per page:
1 - 10 of 23
BioCentury | Nov 20, 2014
Cover Story

Tapping TOPK

...Sciences Inc. and Galen Ltd. and Myocet liposomal doxorubicin from Teva Pharmaceutical Industries Ltd. and Sopherion Therapeutics LLC...
...U.K. Nerviano Medical Sciences s.r.l. , Nerviano, Italy OncoTherapy Science Inc. (Tokyo:4564), Kawasaki City, Japan Sopherion Therapeutics LLC...
BioCentury | Jul 5, 2010
Finance

2H10 milestones

...Osaka:4506) Calsed amrubicin Second-line small cell lung cancer (SCLC) Ph III data YE10 Cephalon Inc. (NASDAQ:CEPH)/Sopherion Therapeutics LLC...
BioCentury | Apr 8, 2010
Distillery Techniques

Technology: Drug delivery

...treat cancer. Johnson & Johnson markets Doxil doxorubicin to treat several cancers. Cephalon Inc. and Sopherion Therapeutics LLC...
BioCentury | Jan 11, 2010
Clinical News

Myocet doxorubicin regulatory update

...FDA granted Fast Track designation for Sopherion's Myocet nonpegylated liposomal doxorubicin for first-line treatment of HER2-positive...
...is in a Phase III trial for the indication, with results expected by year end. Sopherion...
...which was acquired by Cephalon (see BioCentury, Dec. 12, 2005). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Sopherion Therapeutics LLC...
BioCentury | Mar 23, 2009
Clinical News

Myocet doxorubicin: Completed Phase III enrollment

...an open-label, international Phase III trial evaluating Herceptin trastuzumab and paclitaxel with or without Myocet. Sopherion...
...Basel, Switzerland) and Genentech Inc. (NYSE:DNA, South San Francisco, Calif.). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Sopherion Therapeutics LLC...
BioCentury | Mar 2, 2009
Company News

Sopherion management update

Sopherion Therapeutics LLC , Princeton, N.J. Business: Cancer Hired: Marcel Rozencweig as senior EVP of clinical affairs, while remaining an adjunct associate professor of medicine at New York University WIR Staff cancer Other...
BioCentury | Feb 20, 2009
Financial News

Sopherion raises $55 million

...Venture Partners/Sprout Group; ProQuest Investments; Canaan Partners; Commerce Bank; and NewSpring Capital in the round. Sopherion's...
...Myocet liposomal doxorubicin, which is in Phase III testing to treat first-line metastatic breast cancer. Sopherion...
BioCentury | Feb 9, 2009
Clinical News

Myocet doxorubicin: Phase I/II data

...of metastatic breast cancer in combination with cyclophosphamide. Cephalon has European rights to Myocet, and Sopherion...
...by Roche and Genentech Inc. (NYSE:DNA, South San Francisco, Calif.). Cephalon Inc. (NASDAQ:CEPH), Frazer, Pa. Sopherion Therapeutics LLC...
BioCentury | Jan 15, 2009
Distillery Therapeutics

Indication: Cancer

...for angina and hypertension. Myocet doxorubicin, a liposomal formulation of doxorubicin from Cephalon Inc. and Sopherion...
BioCentury | Sep 25, 2008
Distillery Techniques

This Week in Techniques

...additional preclinical cancer models. Myocet doxorubicin, a liposomal formulation of doxorubicin from Cephalon Inc. and Sopherion...
Items per page:
1 - 10 of 23